Posted by Michael Wonder on 06 Aug 2019
Knight Therapeutics and pan-Canadian Pharmaceutical Alliance reach agreement for Probuphine for opioid dependence
6 August 2019 - AB, SK and NIHB are the first public drug plans to fund Probuphine recognising benefits of new treatment option.
Knight Therapeutics announced today that it has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent regarding Probuphine (buprenorphine hydrochloride subdermal implant).
Subsequent to the agreement reached with pCPA, as at August 5, 2019, Probuphine is listed for reimbursement through the public insurance plans administered by Alberta, Saskatchewan and the Non-Insured Health Benefit (NIHB). Knight is actively working with other jurisdictions to finalise listings across the country to ensure Canadian patients have public access to this novel treatment option.
